{
  "state": "south-dakota",
  "path": "title-title-58-insurance/chapter-chapter-29g-drug-discount-program-protections",
  "sections": [
    {
      "id": "section-58-29g-1",
      "number": "58-29G-1",
      "heading": "Definitions.Section 58-29G-2 - General protections--Exclusions",
      "text": "58-29G-1. Definitions.\n\nTerms used in this chapter mean:\n\n(1)\"Pharmaceutical manufacturer,\" any person engaged in the business of preparing, producing, converting, processing, packaging, labeling, or distributing a prescription drug, but not including a wholesale distributor or dispenser;\n\n(2)\"Pharmacy,\" any place within or outside this state, licensed by the State Board of Pharmacy, where drugs are dispensed, and pharmaceutical care is provided to residents of this state;\n\n(3)\"340B drug,\" a drug purchased through the 340B drug discount program by a 340B entity;\n\n(4)\"340B drug discount program,\" a program that imposes limitations on the prices of drugs purchased by covered entities, in accordance with 42 U.S.C. §256b (January 1, 2025); and\n\n(5)\"340B entity,\" a covered entity as defined in 42 U.S. C. §256b(a)(4) (January 1, 2025).\n\nSource: SL 2025, ch 198, §2.",
      "history": "",
      "source_url": "https://law.justia.com/codes/south-dakota/title-58/chapter-29g/section-58-29g-1/"
    },
    {
      "id": "section-58-29g-2",
      "number": "58-29G-2",
      "heading": "General protections--Exclusions.",
      "text": "58-29G-2. General protections--Exclusions.\n\nA pharmaceutical manufacturer may not, directly or indirectly, deny, restrict, or prohibit the acquisition of a 340B drug or the delivery of a 340B drug to a location that is authorized to receive the drug by a 340B entity or pharmacy, unless receipt of the 340B drug is prohibited by federal law.\n\nNothing in this section requires a pharmaceutical manufacturer to provide a 340B drug price discount to a pharmacy.\n\nNothing in this section prohibits a pharmaceutical manufacturer from limiting distribution of a drug in accordance with 21 U.S.C. §355-1 (January 1, 2025).\n\nSource: SL 2025, ch 198, §3.",
      "history": "",
      "source_url": "https://law.justia.com/codes/south-dakota/title-58/chapter-29g/section-58-29g-2/"
    },
    {
      "id": "section-58-29g-3",
      "number": "58-29G-3",
      "heading": "Requiring claim or utilization data restricted--Exclusion.",
      "text": "58-29G-3. Requiring claim or utilization data restricted--Exclusion.\n\nA pharmaceutical manufacturer may not, directly or indirectly, require a 340B entity or pharmacy to submit any claim or utilization data, as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity, unless the claim or utilization data sharing is required by federal law.\n\nNothing in this section prohibits a pharmaceutical manufacturer from conducting an audit of a 340B entity, in accordance with 42 U.S.C. §256b(a)(5)(C) (January 1, 2025).\n\nSource: SL 2025, ch 198, §4.",
      "history": "",
      "source_url": "https://law.justia.com/codes/south-dakota/title-58/chapter-29g/section-58-29g-3/"
    },
    {
      "id": "section-58-29g-4",
      "number": "58-29G-4",
      "heading": "Civil action--Damages--Attorney’s fees.",
      "text": "58-29G-4. Civil action--Damages--Attorney’s fees.\n\nIn addition to any other remedy provided by law, a 340B entity or a pharmacy may file a civil action against a pharmaceutical manufacturer for a violation of this chapter, and may request injunctive relief, actual and consequential damages, and reasonable attorneys' fees and costs.\n\nSource: SL 2025, ch 198, §5.",
      "history": "",
      "source_url": "https://law.justia.com/codes/south-dakota/title-58/chapter-29g/section-58-29g-4/"
    }
  ]
}